Home > Press > MedThink Communications Retained by NanoBio Corporation
MedThink Communications, an innovator in health care communications and public relations, has been retained by NanoBio Corporation to promote its novel technology that uses nano-sized particles to eradicate skin infections, without harming normal tissue.
MedThink Communications Retained by NanoBio Corporation
RALEIGH, NC | Posted on September 4th, 2007
MedThink will implement a scientifically based communications program that includes public relations, advocacy development and medical communications in order to advance NanoBio's lead products, two topical agents (NB-001 and NB-002) that safely treat cold sores and toenail fungus.
"The depth of our scientific expertise allows us to transform highly technical information into readily understandable messages that resonate with a company's key audiences," said Scott Goudy, partner at MedThink. "Our scientific staff works in tandem with the promotional and public relations teams to build a comprehensive, integrated communications program."
NanoBio's scientific platform is in various stages of testing for skin infections, shingles, eye infections, vaginitis, genital herpes, and mucosal vaccines against influenza and hepatitis B. The mucosal vaccines, delivered nasally, will carry antigens that serve to alert and rouse the immune system into action against each respective infection. In the future, NanoBio plans to apply its technology to other mucosal vaccines that may include tuberculosis, small pox, anthrax and other viral and bacterial diseases.
About MedThink Communications
MedThink Communications is an award-winning, full-service medical agency whose communication services capture the essence of your brand and transform it into compelling messages that inspire your target audiences. Our innovative approach to advertising, medical communications, public relations, media planning and placement, sales training and marketing consulting serves as the perfect complement to strengthen our health care partners' competitive edge. ( http://www.medthink.com/ )
NanoBio(R) Corporation is a privately held biopharmaceutical company focused on developing and commercializing anti-infective products and mucosal vaccines, based on its patented NanoStat(TM) technology platform. Founded in 2000 as a spin-out from the Center for Biologic Nanotechnology at the University of Michigan, NanoBio's lead product candidates target treatments for herpes labialis (cold sores), onychomycosis (nail fungus) and mucosal vaccines for hepatitis B and influenza. The company's pipeline also includes products that target genital herpes, herpes zoster (shingles) and methicillin-resistant Staphylococcus aureus (MRSA).
For more information, please click here
Copyright © PR Newswire Association LLC.
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Vegetable oil ingredient key to destroying gastric disease bacteria: In mice, therapeutic nanoparticles dampen H. pylori bacteria and inflammation that lead to ulcers and gastric cancer November 25th, 2014
Research reveals how our bodies keep unwelcome visitors out of cell nuclei November 24th, 2014
ASU, IBM move ultrafast, low-cost DNA sequencing technology a step closer to reality November 24th, 2014
An Inside Job: UC-Designed Nanoparticles Infiltrate, Kill Cancer Cells From Within November 24th, 2014
SEMATECH to Showcase Innovation and Advances in Manufacturing at SEMICON Japan 2014: SEMATECH experts will share the latest techniques, emerging trends and best practices in advanced manufacturing strategies and methodologies November 26th, 2014
Australian startup creates world’s first 100% cotton hydrophobic T-Shirts November 26th, 2014
The mysterious 'action at a distance' between liquid containers November 26th, 2014
'Giant' charge density disturbances discovered in nanomaterials: Juelich researchers amplify Friedel oscillations in thin metallic films November 26th, 2014
Mining entrepreneur Julian Malnic Joins Deep Space Industries’ Board: Deep Space Industries welcomes a prolific mining entrepreneur and accomplished company builder, Julian Malnic, to its Board of Directors November 14th, 2014
SEMATECH Names Ronald Goldblatt Permanent Chief Executive Officer November 7th, 2014
First Canada Excellence Research Chair gets $10 million from the federal government for oilsands research at the University of Calgary: Federal government announces prestigious research chair to study improving oil production efficiency October 19th, 2014
VDMA photonics steering committee with new members stronger than ever October 14th, 2014